Since some pathways (e.g., NF-κB signaling [43], Notch signaling pathway [44], and PI3K/Akt signaling pathway [45]) were demonstrated to participate in atherosclerosis development; whether the miR-146-5p/TRAF6 axis can regulate these pathways in Ox-LDL-treated VSMCs should be investigated. The gene discussed is AKT1; the disease is atherosclerosis.